Komori
SanBio (4592) · RiskFirst stated

Dependence on External Service Providers

First written in FY2023. . Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk of Outsourcing Provider Disruption or Contract Termination in Pharmaceutical DevelopmentA theme 10 companies write about · 11 as a headwind · 0 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2023First statedAnnual report

    「The Group conducts its own R&D and the design of its manufacturing processes, which constitute its core competencies, but outsources nonclinical and clinical trials, the manufacture of regenerative cell products and other operations to external contractors such as CROs (contract research organizations) and CMOs (contract manufacturing organizations).」

    The Company has outsourced nonclinical trials, clinical trials and the manufacture of regenerative cell products to external contractors such as CROs and CMOs, and has disclosed the potential impact on operating results and financial position if it is unable to obtain their support as a new risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for SanBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Dependence on External Service Providers | SanBio Company Limited (4592) | Komori